Caxton Corp
- SEC CIK
- 0001388551
- Latest filing
- Aug 13, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 15
- +3 vs. Q3 2024
- Portfolio value
- $16.6M
- −$7.53M (−31.1%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ACETAdicet Bio, Inc. | COM | 17,488 | $16.8K | 0.1% | 00.0% | Unchanged | History |
| CNTXContext Therapeutics Inc. | COM | 18,403 | $19.3K | 0.1% | 00.0% | Unchanged | History |
| CBIOCrescent Biopharma, Inc. | COM | 203,578 | $50.9K | 0.3% | +203,578 | New | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 16,393 | $53.3K | 0.3% | +16,393 | New | History |
| CRDFCardiff Oncology, Inc. | COM | 13,287 | $57.7K | 0.3% | +13,287 | New | History |
| CMPXCompass Therapeutics, Inc. | COM | 43,465 | $63.0K | 0.4% | 00.0% | Unchanged | History |
| KYTXKyverna Therapeutics, Inc. | COM | 22,981 | $86.0K | 0.5% | 00.0% | Unchanged | History |
| LXEOLexeo Therapeutics, Inc. | COM | 17,851 | $117.5K | 0.7% | 00.0% | Unchanged | History |
| BCAXBicara Therapeutics Inc. | COM | 10,941 | $190.6K | 1.1% | 00.0% | Unchanged | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 34,073 | $237.1K | 1.4% | 00.0% | Unchanged | History |
| GLDSPDR Gold Trust | ETF | 1,169 | $283.1K | 1.7% | +1,169 | New | History |
| BRK.BBerkshire Hathaway Inc | Stock | 1,133 | $513.6K | 3.1% | −18−1.6% | Reduced | History |
| SPYSPDR S&P 500 ETF Trust | ETF | 2,823 | $1.65M | 9.9% | −44−1.5% | Reduced | History |
| RZLTRezolute, Inc. | COM NEW | 1,318,967 | $6.46M | 38.8% | 00.0% | Unchanged | History |
| XERSXeris Biopharma Holdings, Inc. | COM | 2,015,157 | $6.83M | 41.1% | −3,098,191−60.6% | Reduced | History |
Sold out since Q3 2024 (1)
Positions held at the end of Q3 2024 that are gone from this filing.